Implantable neurological technology has advanced drastically, offering a return to normalcy for some people with neurological ...
Glenmark’s current portfolio consists of 195 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' INGREZZA drug to treat movement disorders associated with Huntington's disease, the company ...
The recent fiasco concerning Nestle's Cerelac and MDH and Everest's masala mayhem has put the spotlight on the safety of the ...